8-K
filed March 27, 2023, 7:59 PM ET
CIK 0001659352
other material
confidence high
sentiment negative
materiality 0.85
Codiak BioSciences, Inc.: going-concern / distress — Codiak BioSciences files Chapter 11, seeks asset sale, cuts 69% of staff, top executives exit
Codiak BioSciences, Inc.
- Filed voluntary Chapter 11 petition in Delaware on March 27, 2023; intends to sell substantially all assets through a court-supervised process.
- Reduced workforce by 34 employees (69%); estimates ~$1.12M in severance and termination costs.
- CEO Douglas Williams, CFO Linda Bain, CMO David Mauro, CSO Sriram Sathyanarayanan, Chief Legal Officer Yalonda Howze, and VP HR Nicole Barna departing in early April 2023; Williams remains on board.
- Appointed Paul Huygens of Province, LLC as Chief Restructuring Officer to manage the sale process and operations during Chapter 11.
Key facts
Extracted from this filing and checked against the source text.
Distress & Bankruptcy
SEC 8-K Item 1.03
confidence 0.9
Codiak BioSciences, Inc. entered chapter 11 in United States Bankruptcy Court for the District of Delaware (petition 2023-03-27).
- Proceeding
- chapter 11
- Court
- United States Bankruptcy Court for the District of Delaware
- Petition
- 2023-03-27
Exact text from the filing
On March 27, 2023, Codiak BioSciences, Inc. (the “Company”) filed a voluntary petition (the “Bankruptcy Petition”) for relief under Chapter 11 of Title 11 (“Chapter 11”) of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), thereby commencing a Chapter 11 case for the Company (Case No. 23-10350).
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
David Mauro departed as Chief Medical Officer at Codiak BioSciences, Inc..
- Action
- will be leaving
- Role
- Chief Medical Officer
Exact text from the filing
The departures of Dr. Williams, Ms. Bain, Dr. Mauro, Dr. Sathyanarayanan and Ms. Barna will be effective as of April 7, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Nicole Barna departed as Senior Vice President, Human Resources at Codiak BioSciences, Inc..
- Action
- will be leaving
- Role
- Senior Vice President, Human Resources
Exact text from the filing
The departures of Dr. Williams, Ms. Bain, Dr. Mauro, Dr. Sathyanarayanan and Ms. Barna will be effective as of April 7, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Yalonda Howze resigned as Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary at Codiak BioSciences, Inc..
- Action
- resigned
- Role
- Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary
Exact text from the filing
Ms. Howze notified the Company of her resignation from her position, to be effective as of April 4, 2023, on March 24, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Douglas E. Williams departed as President and Chief Executive Officer at Codiak BioSciences, Inc..
- Action
- will be leaving
- Role
- President and Chief Executive Officer
Exact text from the filing
The departures of Dr. Williams, Ms. Bain, Dr. Mauro, Dr. Sathyanarayanan and Ms. Barna will be effective as of April 7, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Sriram Sathyanarayanan departed as Chief Scientific Officer at Codiak BioSciences, Inc..
- Action
- will be leaving
- Role
- Chief Scientific Officer
Exact text from the filing
The departures of Dr. Williams, Ms. Bain, Dr. Mauro, Dr. Sathyanarayanan and Ms. Barna will be effective as of April 7, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Linda C. Bain departed as Chief Financial Officer and Treasurer at Codiak BioSciences, Inc..
- Action
- will be leaving
- Role
- Chief Financial Officer and Treasurer
Exact text from the filing
The departures of Dr. Williams, Ms. Bain, Dr. Mauro, Dr. Sathyanarayanan and Ms. Barna will be effective as of April 7, 2023.
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
Codiak BioSciences, Inc. announced a restructuring with charges of approximately $1,120,000 (thirty-four (34) employees, or 69%).
- Type
- restructuring
- Charge
- approximately $1,120,000
- Headcount
- thirty-four (34) employees, or 69%
Exact text from the filing
The Company estimates that it will incur approximately $1,120,000 of costs in connection with the reduction in workforce related to severance pay and other related termination benefits.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.